Compare Fulford India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs SUN PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA SUN PHARMA FULFORD INDIA/
SUN PHARMA
 
P/E (TTM) x 398.8 27.0 1,476.4% View Chart
P/BV x 6.2 2.3 266.4% View Chart
Dividend Yield % 0.1 0.7 12.4%  

Financials

 FULFORD INDIA   SUN PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
SUN PHARMA
Mar-19
FULFORD INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs942679 138.8%   
Low Rs450375 119.9%   
Sales per share (Unadj.) Rs691.4121.1 570.7%  
Earnings per share (Unadj.) Rs11.513.4 85.7%  
Cash flow per share (Unadj.) Rs15.420.7 74.3%  
Dividends per share (Unadj.) Rs2.002.75 72.7%  
Dividend yield (eoy) %0.30.5 55.1%  
Book value per share (Unadj.) Rs380.0172.6 220.2%  
Shares outstanding (eoy) m3.902,399.26 0.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.4 23.1%   
Avg P/E ratio x60.739.4 154.1%  
P/CF ratio (eoy) x45.325.5 177.8%  
Price / Book Value ratio x1.83.1 60.0%  
Dividend payout %17.420.6 84.9%   
Avg Mkt Cap Rs m2,7141,264,650 0.2%   
No. of employees `0000.417.5 2.5%   
Total wages/salary Rs m50559,671 0.8%   
Avg. sales/employee Rs Th6,073.016,608.1 36.6%   
Avg. wages/employee Rs Th1,137.43,409.6 33.4%   
Avg. net profit/employee Rs Th100.71,833.8 5.5%   
INCOME DATA
Net Sales Rs m2,696290,659 0.9%  
Other income Rs m12510,255 1.2%   
Total revenues Rs m2,822300,914 0.9%   
Gross profit Rs m-4663,076 -0.1%  
Depreciation Rs m1517,533 0.1%   
Interest Rs m105,553 0.2%   
Profit before tax Rs m5450,246 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m106,009 0.2%   
Profit after tax Rs m4532,093 0.1%  
Gross profit margin %-1.721.7 -7.9%  
Effective tax rate %17.712.0 147.8%   
Net profit margin %1.711.0 15.0%  
BALANCE SHEET DATA
Current assets Rs m1,738310,692 0.6%   
Current liabilities Rs m545173,396 0.3%   
Net working cap to sales %44.347.2 93.7%  
Current ratio x3.21.8 178.1%  
Inventory Days Days4899 48.9%  
Debtors Days Days4112 3.9%  
Net fixed assets Rs m12232,477 0.0%   
Share capital Rs m392,399 1.6%   
"Free" reserves Rs m1,443411,691 0.4%   
Net worth Rs m1,482414,091 0.4%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m2,077646,938 0.3%  
Interest coverage x6.710.0 66.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.4 289.0%   
Return on assets %2.65.8 44.9%  
Return on equity %3.07.8 38.9%  
Return on capital %4.310.2 42.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1766,025 0.0%   
Fx outflow Rs m67338,610 1.7%   
Net fx Rs m-65627,415 -2.4%   
CASH FLOW
From Operations Rs m9021,965 0.4%  
From Investments Rs m105-6,813 -1.5%  
From Financial Activity Rs m-14-27,305 0.1%  
Net Cashflow Rs m181-8,442 -2.1%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 5.1 74.1%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 8.3 255.4%  
Shareholders   4,783 133,026 3.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  

Compare FULFORD INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - ALEMBIC PHARMA COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS